Skip to main
MNKD

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

MannKind is supported by a stronger, more diversified growth story that is increasingly centered on royalty and collaboration revenue, with Tyvaso DPI and ralinepag DPI expanding visibility into durable cash flows. The company also has multiple internally controlled catalysts, including the Afrezza pediatric PDUFA, FUROSCIX ReadyFlow autoinjector PDUFA, and 3Q26 MNKD-201 IPF data, while 1Q26 revenue of $90.2M and cash and investments of $134M show a business with meaningful scale and a cleaner balance sheet. Positive launch momentum in Afrezza, management’s $110M to $120M 2026 FUROSCIX target, and encouraging early MNKD-201 tolerability data reinforce a favorable risk-reward profile.

Bears say

MannKind is facing a fundamentally challenging outlook because its revenue base depends heavily on products and partners that may underperform, including Afrezza, V-Go, and Tyvaso DPI, while consensus already anticipates royalty revenue declining from 2027 onward. The company also carries meaningful regulatory and clinical risk, as pipeline candidates such as ralinepag DPI (MNKD-1501) may fail to secure approval in the United States or Europe, delaying profitability and eroding the value of its shares. In addition, MannKind may need additional funding before reaching profitability, and its dependence on United Therapeutics, Biomm Sa, Australasian Medical & Scientific, and future collaboration partners creates execution risk outside its control.

MannKind (MNKD) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 8 analysts, MannKind (MNKD) has a Buy consensus rating as of Oct 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.